Login / Signup

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Samuel J KlempnerSteven B MaronLeah ChaseSamantha LomnickiZev A WainbergDaniel V T Catenacci
Published in: The oncologist (2018)
Results of this study provide initial support for the safety and efficacy of second-line (2L) FOLFIRI-ramucirumab (ram) after progression on first-line platinum/fluoropyrimidine in patients with gastroesophageal adenocarcinoma (GEA). The overall response, progression-free survival, overall survival, and toxicity profile compare favorably with paclitaxel (pac) + ram and highlight the importance of the ongoing phase II RAMIRIS trial examining FOLFIRI-ram versus pac + ram in 2L GEA (NCT03081143). FOLFIRI-ram may warrant consideration for inclusion as an alternate regimen in consensus guidelines for GEA.
Keyphrases
  • phase ii
  • metastatic colorectal cancer
  • free survival
  • clinical trial
  • wild type
  • open label
  • phase iii
  • squamous cell carcinoma
  • clinical practice
  • study protocol
  • oxidative stress
  • randomized controlled trial